Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

· Orismilast is a potential best-in-class PDE4 inhibitor in Phase 2 clinical development for the treatment of atopic dermatitis, psoriasis, and hidradenitis suppurativa · Innovent will be granted exclusive rights to research, develop and commercialize orismilast in China (including Mainland China, Hong Kong, Macau and Taiwan) · UNION will receive USD 20 million upfront and be entitled to receive additional milestone payments of up to USD 247 million as well as tiered royalties on sales of orismilast in China Hellerup, Denmark, San Francisco, U.S. and Suzhou, China, 28 September

Finnair moves forward with refinancing plan: sale and leaseback agreement for four A350 aircraft closed for cash proceeds in excess of 400 MUSD

Finnair Plc             Stock Exchange Release            28 September 2021 at 9.00 a.m. EEST  In conjunction with Finnair’s efforts to emerge from the corona crisis, the company is proceeding with its refinancing plan and has finalised a sale and leaseback arrangement for four of its Airbus A350 aircraft. In the arrangement, Finnair sold these aircraft – delivered between June 2017 and February 2019 – and has leased them back for its own operation. The operating lease period is, on average, 12 years and the counterparties are GE Capital Aviation Services (“GECAS”) and Pacific Investment

BONESUPPORT – SUPPLEMENTARY US DENOVO APPLICATION SUBMITTED

Lund, Sweden, 08:00 CET, 28-09-21 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) and can potentially result in an approval in Q1 of 2022. In February of this year, the FDA requested further data and clarifications on BONESUPPORT’s DeNovo application. The

Peab renovates and expands elementary school in Helsinki

Peab has been commissioned to expand and renovate an elementary school in Pohjois Haaga in Helsinki. The customer is the city of Helsinki and the contract is worth EUR 14 million.The project entails a total renovation as well as construction of two new buildings. The current school building consists of three parts. “We have a lot of experience renovating school buildings in the capital region. We’re pleased that we can now carry out this project and continue to take advantage of the expertise in our organization,” says Marko Rinkinen, Region Manager Peab. The project is a turnkey

Patent in India enables a large future market for myFC's technology

One of myFC’s patents has been approved by the Indian Patent Office. The patent protects a smooth and gentle method for efficiently starting up the fuel cells and transitioning to a power-generating phase, while maintaining the long life of the fuel cells.India, with a population of almost 1.4 billion, is a country that invests heavily in hydrogen technology, focusing on using energy resources more efficiently without losing competitiveness, and on improving environmental conditions, especially in highly populated urban environments.Green hydrogen technology has great advantages in terms of

Sedana Medical receives approval in Germany

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany.The approval applies to the drug Sedaconda (isoflurane) for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in Germany. The application has been approved by the German pharmaceutical authority BfArM and is based on the DCP approval Sedana Medical received in July. Since the European DCP approval in July 2021, Sedaconda (isoflurane) has now received national approvals in

Changes in Teknos Group Management – Edward Skärström, CIO, leaves the company

Edward Skärström, CIO, has decided to leave Teknos Group. The recruitment process of successor will be started immediately. Edward will continue in his current role as CIO, Teknos Management Team member, until the new CIO is recruited.Edward Skärström, CIO, has decided to leave Teknos Group. Edward joined Teknos in 2015. In 2017 he was appointed Chief Information Officer (CIO) for Teknos Group and the Group ICT organization was formed. Since 2019 Edward has been a member of Teknos Management Team (TMT). “Eddi’s structured manner, calm way of addressing topics and ability to spar and

Expo 2020: LKAB and Sweden show the way towards a sustainable future

On October 1st Expo 2020 opens in Dubai, where the Swedish Government together with the industry will present new technology and innovations on a global arena. As one of several official partners, LKAB is showcasing the most recent advances in the iron and steel industry that pave the way for a necessary global transition.- There is tremendous global interest in what is happening in our part of the world right now. We are breaking new ground on the journey towards fossil-free iron and steelmaking, which is the greatest thing we can do together for the climate. Expo is a unique opportunity

Polygon completes early redemption of all 2018/2023 notes

THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, WITHIN OR TO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS. SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.As previously announced, Polygon AB (publ) (the “Company” or “Polygon”) has resolved on a voluntary redemption in full of all outstanding senior secured fixed rate notes with ISIN SE0010830950 (

Microscopic metavehicles powered by nothing but light

  Click here to watch a video of the metavehicles in action Researchers from Chalmers University of Technology, Sweden, have succeeded in creating tiny vehicles powered by nothing but light. By layering an optical metasurface onto a microscopic particle, and then using a light source to control it, they succeeded in moving the tiny vehicles in a variety of complex and precise ways – and even using them to transport other objects.  Light has an inherent power to move microscopic objects – a property previously used to

Invitation to Kungsleden’s presentation of interim report for January–September 2021

On Tuesday, 19 October, Kungsleden will publish its interim report for January–September 2021. At 10:00 a.m. (CEST), Kungsleden invites investors, financial analysts and the press to a live presentation of our interim report where CEO Biljana Pehrsson and Deputy CEO and CFO Ylva Sarby Westman will comment on the company’s performance.The report will be published at 6:55 a.m. (CEST) and will be available here . As of 9:00 a.m. (CEST) the slides from the presentation will be available from here 

Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

Stockholm, September 28, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD). The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early Alzheimer’s disease and

Swedish Semiconductor Startup AlixLabs Raises USD 1 Million Seed Capital

Almi Invest is investing close to SEK 3 million in AlixLabs, which is developing a new method for manufacturing semiconductor components cheaper and faster. Private investors, including NHL professionals Michael, Alexander and William Nylander, are also participating in the issue for a total of SEK 9 million (USD 1 million). The funds will be used for product development and validation of the APS-technology.Semiconductor components build up the computer chips found in virtually all electronic products, such as smartphones, servers, game consoles, computers and cars. They can be described as

ShaMaran and its President & CEO Dr. Adel Chaouch Selected as 2021 S&P Global Platts Global Energy Awards Finalist

VANCOUVER, BRITISH COLUMBIA, Sept. 27, 2021 /CNW/ – ShaMaran Petroleum Corp. (“ShaMaran” or the “Company”) (SNM: TSXV and Nasdaq First North Growth Market (Sweden)) is pleased to announce that ShaMaran and separately Dr. Adel Chaouch, the Company’s President and CEO, have both been named a finalist in the 23[rd] annual S&P Global Platts Global Energy Awards. The 2021 Finalists were announced on September 23, 2021 by program host S&P Global Platts, the leading global provider of energy and commodities information and spot market benchmarks. ShaMaran is a finalist in the category “Award of

SGL International A/S announces approval of written procedure and amendments to the terms and conditions of the bonds

SGL International A/S (the "Issuer", and together with TransGroup Global Inc., and their respective subsidiaries from time to time, “SGL” or the “Group”) today announces the successful completion of the written procedure that was initiated on 1 September 2021 in relation to the Company’s outstanding up to EUR 315,000,000 senior secured bonds with ISIN SE0013101219 and up to EUR 350,000,000 senior secured bonds with ISIN SE0015810759 (jointly the “Senior Bonds”), regarding certain waivers and amendments to the terms and conditions of the Senior Bonds (the “Proposal”). A sufficient number

Simba Mattress Review | Save 35% On Simba Hybrid Mattresses, Simba Sleep Discount Code

The Simba Hybrid mattress was developed as a result of a comprehensive sleeper study conducted by the Sleep to Live Institute in the United States. As a result, the brand has created a mattress that is meant to accommodate people of all sizes, shapes, and sleeping styles. Latex, conical pocket springs, responsive memory foam, and 7-zone support foam are among the materials that make up this mattress. The Simba mattress is a medium to firm mattress that is responsive and supportive, and it is particularly adept at conforming to the needs of side and back sleepers. Although it is more expensive,

Correction of date in today's press release regarding early redemption of outstanding corporate bonds

In the press release published by Nordisk Bergteknik earlier today regarding early redemption of outstanding corporate bonds and entering of facilities agreements with Nordea and Swedbank, a date was stated in the second paragraph regarding the date for the registered holder incorrectly to 24 September. The correct day is 15 October. For further clarification, early redemption of the corporate bond is conditioned by, among other things, the receipt of bank financing, as stated in the notification sent to the bondholders as of 27 September. Correct press release follows below.

Bioretec completes a private placement raising EUR 1.74 million

Bioretec Ltd                         Inside information                27 September 2021 at 10.00 p.m. EESTTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Bioretec Ltd ("Bioretec" or the "Company") announced on 20 September 2021 that it was planning a directed share issue of up to approximately EUR 4.0 million for institutional investors and a limited

American Shipping Company ASA: Completed buyback of own shares and sale of treasury shares to CEO and CFO

27 September 2021 - Reference is made to American Shipping Company ASA’s (“ASMC” or the “Company”) stock exchange notice dated 16 September 2021 where AMSC announced its intent to purchase 45,000 treasury shares in connection with its incentive scheme for employees. AMSC has completed the buyback of 45,000 treasury shares in the Company on Oslo Børs at an average price of NOK 31.90 per share, which implies a total consideration of NOK 1,435,598. The purchase of treasury shares was carried out in accordance with an authorization granted by the Annual General Meeting of the Company held on 20

Mercell Holding – Result of offer under the Employment Share Ownership Program and share capital increase

Oslo, 27 September 2021: Reference is made to Mercell Holding ASA's (the "Company") stock exchange announcement earlier today, on 27 September 2021, regarding the result of the offer of new shares under the Employment Share Ownership Program for the group's employees in the EU, EEA and the UK  (the "Employment Share Ownership Program") and the board of directors' resolution to increase the share capital of the Company. The following primary insiders of the Company have today, on 27 September 2021, applied for, been allocated and subscribed new shares in the Company at the offer price of

Update on operations and financial targets for the fiscal year 2020/2021

CS MEDICA A/S’s (”CS MEDICA” or the ”Company”) will adjust its financial targets for the fiscal year 2020/2021. The previously communicated financial target of DKK 7 million will be adjusted to approx. DKK 3.6 million. The completion of the process of testing and getting approval by the ethics committee in India was prolonged due to Covid-19, in turn impacting and postponing the finalization of an agreement. The Company is experiencing great interest in the product portfolio and sees no reason to revise future objectives, rather, the Company expects that ongoing in-depth dialogues and already

Mercell Holding – Result of offer under the Employment Share Ownership Program and share capital increase

Oslo, 27 September 2021: Reference is made to Mercell Holding ASA's (the "Company") stock exchange announcement on 20 September 2021, regarding the offer of new shares under the Employment Share Ownership Program for the group's employees in the EU, EEA and the UK (the "Employment Share Ownership Program"). The deadline for acceptance of the offer in the Employment Share Ownership Program expired today, on 27 September 2021, at 17:00 hours (CEST). The offer price for the shares in the Offer has been set to NOK 5.387432221 (the "Offer Price"). The Offer Price equals the volume-weighted

Storskogen publishes prospectus and announces price for its initial public offering and listing of its B-shares on Nasdaq Stockholm

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. Neither this announcement, nor anything contained herein, shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information contained in a prospectus in its final form (the “Prospectus”) that has been

GomSpace signs a contract with SpaceAble to enhance the sustainability of Low Earth Orbit

GomSpace enters into an agreement with SpaceAble, to enhance the sustainability of Low Earth Orbit (LEO). The contract is worth 21MSEK and the project will begin in 2021 with expected delivery in late 2023. The mission is designed to enhance the sustainability of LEO. By tracking the inherent risk of space weather thanks to SpaceAble’s technology and GomSpace´s platform, we are working at a larger level on providing the market with a comprehensive solution—which includes both inspector satellites and critical space data—to strengthen the resilience of new constellations.  “We are

There are no items matching the current filter
There are no more items matching the current filter
Back to top